pharmaceuticals

Thursday’s Top 4 ASCO Movers

The 55th Annual Meeting of the American Society of Clinical Oncology (ASCO) is scheduled for May 31 to June 4 in Chicago. This meeting always brings big swings in the ...
Read Full Story »

Can Danaher Walk Away From the Buyout of GE’s Biopharma Unit?

If there is one former Dow Jones industrial average leader that is in need of serious help, look no further than General Electric Co. (NYSE: GE). A new CEO has ...
Read Full Story »

The Best Biotech ETFs to Buy Ahead of ASCO

The 55th annual meeting of the American Society of Clinical Oncology (ASCO) is just around the corner. Biotech and pharmaceutical companies will descend on Chicago for a five-day all-out conference ...
Read Full Story »

Big Pharma Scares Off Short Sellers

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

Why Mylan Is Getting Absolutely Crushed

When Mylan N.V. (NASDAQ: MYL) released its first-quarter financial results before the markets opened on Tuesday, the company posted $0.82 in earnings per share (EPS) and $2.5 billion in revenue. ...
Read Full Story »

5 ETFs Targeting a Healthier America

Eating a nutritious and well-balanced diet, exercising regularly and abstaining from bad habits like smoking — while by no means a guarantee — greatly increase one’s odds of living a long ...
Read Full Story »

Osmotica Pharma Makes Significant Headway With Ptosis Treatment

Osmotica Pharmaceuticals PLC (NASDAQ: OSMT) is working to treat ptosis, or droopy eyelid. While this can occur for a number of reasons, Osmotica has made some headway in the treatment ...
Read Full Story »

What to Expect When Mylan Reports Tuesday

Mylan N.V. (NASDAQ: MYL) is scheduled to release its first-quarter financial results before the markets open on Tuesday. The consensus forecast calls for $0.79 in earnings per share (EPS) and ...
Read Full Story »

Big Pharma Scares Off Short Sellers

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

Top Biotech Stocks and ETFs: A Sector in Trouble or a Huge Bargain

When the stock market is hitting record highs, it's important to remember that it's really a market of stocks rather than a stock market. Not all companies are created equal. ...
Read Full Story »

Why 5 Lagging Health Care Giants May Be Incredible Buys Now

While the overall stock market has been very strong year to date, with sectors like technology outperforming, the health care sector, which encompasses everything from pharmaceuticals to biotech to medical ...
Read Full Story »

What Drove Johnson & Johnson in Q1

Johnson & Johnson (NYSE: JNJ) released its first-quarter financial results before the markets opened on Tuesday. The health care giant said that it had $2.10 in earnings per share (EPS) ...
Read Full Story »

What to Expect When Johnson & Johnson Reports Tuesday Morning

Johnson & Johnson (NYSE: JNJ) is scheduled to release its first-quarter financial results before the markets open on Tuesday. The consensus estimates are $2.04 in earnings per share (EPS) and ...
Read Full Story »

Unbelievable Swings in Big Pharma Short Interest

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

Should Alnylam Pharma Be Getting More Credit for Its Regeneron Deal?

Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY) and Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) have announced a collaboration to discover, develop and commercialize new RNA interference (RNAi) therapeutics for a broad range of ...
Read Full Story »